目的 觀察瑞舒伐他汀鈣片聯(lián)合前列地爾注射液對糖尿病腎病患者蛋白尿的療效。方法 采用總結性、回顧性研究方法，選擇2015年8月-2018年8月在西安西電集團醫(yī)院內(nèi)分泌科診治的糖尿病腎病患者230例作為研究對象，分為對照組和觀察組，每組各115例。對照組給予前列地爾注射液，10 μg加入100 mL生理鹽水緩慢滴注，1次/d；觀察組在對照組治療的基礎上口服瑞舒伐他汀鈣片10 mg，1次/d。14 d為1個療程，兩組均治療3個療程。觀察兩組的臨床療效，同時比較兩組治療前后的蛋白尿變化情況、腫瘤壞死因子-α（TNF-α）和白細胞介素-6（IL-6）水平、不良反應發(fā)生情況。結果 治療后，觀察組與對照組的總有效率分別為98.3%和87.8%，觀察組顯著高于對照組（P<0.05）。治療后，兩組的24 h尿蛋白定量顯著低于治療前（P<0.05）；且觀察組24 h尿蛋白定量顯著低于對照組（P<0.05）。治療后，兩組的IL-6、TNF-α水平均顯著低于治療前（P<0.05），且觀察組炎癥因子水平顯著低于對照組（P<0.05）。觀察組治療期間的感染、低血糖、低蛋白血癥等不良反應發(fā)生率為7.0%，對照組為8.7%，兩組間差異無統(tǒng)計學意義。結論 瑞舒伐他汀鈣片聯(lián)合前列地爾注射液治療糖尿病腎病患者能更加有效降低蛋白尿含量，抑制炎性反應，提高治療效果，安全性好。

Objective To observe the effects of Rosuvastatin Calcium Tablets combined with Alprostadil Injection on proteinuria in patients with diabetic nephropathy. Methods Using a concluding and retrospective study method, patients (230 cases) with diabetic nephropathy in the Xi'an XD Group Hospital from August 2015 to August 2018 were devided into control and observation groups, and each group had 115 cases. The control group were iv administered with Alprostadil Injection, 10 μg added into 100 mL normal saline, once daily. Patients in the observation group were po administered with 10 mg Rosuvastatin Calcium Tablets on the basis of control group, once daily. 14 d is a course of treatment, both groups are treated for 3 courses. After treatment, the clinical efficacy was evaluated, and the 24 h urinary protein quantitation, TNF-α and IL-6 levels, and adverse reactions in two groups before and after treatment were compared. Results After treatment, the total effective rate of the observation group and the control group after treatment were 98.3% and 87.8%, respectively, and the observation group were higher than control group (P<0.05). After treatment, the 24 hour urine protein levels in two groups were significantly lower than that before treatment (P<0.05), and the 24 hour urine protein levels in the observation group were significantly lower than those in the control group (P<0.05). After treatment, the levels of IL-6 and TNF-α in two groups were significantly lower than those before treatment (P<0.05), and the inflammatory factors levels in the observation group were also significantly lower than those in the control group (P<0.05). The incidence of adverse reactions such as infection, hypoglycemia and hypoproteinemia during the treatment in the observation group was 7.0%, and that of the control group was 8.7%, there were no significant difference compared between two groups. Conclusion Rosuvastatin Calcium Tablets combined with Alprostadil Injection in treatment of diabetic nephropathy can effectively reduce proteinuria, inhibit inflammatory response, improve the therapeutic effect, with good safety.